Elizabeth Wardrop

TL;DR: The development of an in vitro capsid assembly assay based on the association of CA-NC subunits on immobilized oligonucleotides is described and demonstrated that inhibitors that bind within the same site on CA can have distinct binding modes and mechanisms of action.

TL;DR: A novel class of 4,5-dihydro-1H-pyrrolo[3,4-c]pyrazol-6-one ( pyrrolopyrazolone) HIV-1 inhibitors, exemplified by two compounds: BI-1 and BI-2, which may inhibit viral replication by stabilizing the viral capsid.

TL;DR: In vitro, tipranavir-resistant viruses showed cross-resistance to other currently approved protease inhibitors with the exception of saquinavir, demonstrating that the tipranvir resistance phenotype is associated with complex genotypic changes in the protease.

TL;DR: It is determined, for HPV type 11 (HPV-11), that the C-terminal 296 amino acids of E1 are sufficient for interaction with the transactivation domain of E2 in the yeast two-hybrid system and in vitro, and several amino acid substitutions in the phosphate-binding loop abolished E2 binding, indicating that the structural integrity of this domain is essential for the interaction.

TL;DR: The results indicate that the antiviral activity of palinavir is specific to inhibition of the viral protease and occurs at a late stage in the replicative cycle of HIV-1.